Free Trial

Extendicare (TSE:EXE) Shares Cross Above Two Hundred Day Moving Average - What's Next?

Extendicare logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Price breakout: Extendicare shares crossed above their 200‑day moving average (200‑day MA C$21.97), trading as high as C$29.82 and last at C$29.78 on volume of 173,107 shares.
  • Analyst optimism: Multiple firms have raised price targets (up to C$32) and TD upgraded to "buy"; the MarketBeat consensus rating is "Buy" with a consensus target of C$28.64.
  • Fundamentals & dividend: Latest quarter showed EPS C$0.29 on C$462M revenue with a net margin of 5.82% and ROE 47.65%; the company declared a monthly dividend of C$0.0441 (ex‑div Apr 30, payable May 15) implying about a 1.8% yield.
  • MarketBeat previews top five stocks to own in May.

Extendicare Inc. (TSE:EXE - Get Free Report) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of C$21.97 and traded as high as C$29.82. Extendicare shares last traded at C$29.78, with a volume of 173,107 shares changing hands.

Wall Street Analysts Forecast Growth

EXE has been the subject of a number of research reports. National Bank Financial boosted their target price on shares of Extendicare from C$24.50 to C$29.00 and gave the stock an "outperform" rating in a research note on Thursday, February 5th. Canadian Imperial Bank of Commerce raised their price target on shares of Extendicare from C$22.00 to C$32.00 in a research note on Thursday, April 2nd. BMO Capital Markets lifted their price objective on Extendicare from C$24.00 to C$30.00 in a report on Monday, March 2nd. Finally, TD Securities upgraded Extendicare from a "hold" rating to a "buy" rating and boosted their price objective for the stock from C$19.00 to C$32.00 in a research note on Monday, April 6th. One equities research analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the stock. Based on data from MarketBeat, Extendicare has a consensus rating of "Buy" and a consensus target price of C$28.64.

Get Our Latest Research Report on Extendicare

Extendicare Stock Up 0.6%

The business has a fifty day simple moving average of C$26.35 and a two-hundred day simple moving average of C$21.97. The company has a current ratio of 1.37, a quick ratio of 0.98 and a debt-to-equity ratio of 91.85. The company has a market cap of C$2.81 billion, a PE ratio of 26.76 and a beta of 1.18.

Extendicare (TSE:EXE - Get Free Report) last released its earnings results on Thursday, February 26th. The company reported C$0.29 earnings per share (EPS) for the quarter. The business had revenue of C$462.03 million during the quarter. Extendicare had a net margin of 5.82% and a return on equity of 47.65%. As a group, equities research analysts predict that Extendicare Inc. will post 0.6134729 earnings per share for the current year.

Extendicare Announces Dividend

The firm also recently disclosed a monthly dividend, which will be paid on Friday, May 15th. Shareholders of record on Friday, May 15th will be issued a $0.0441 dividend. The ex-dividend date is Thursday, April 30th. This represents a c) dividend on an annualized basis and a yield of 1.8%. Extendicare's dividend payout ratio is presently 44.92%.

About Extendicare

(Get Free Report)

Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Extendicare Right Now?

Before you consider Extendicare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.

While Extendicare currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines